MetaCap

KALA BIO (KALA) vs XORTX Therapeutics (XRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XORTX Therapeutics is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KALA+651.39%XRTX-51.92%
+1015%+451%-113%
Oct 7, 20261 yearNov 20, 2026
KALA+820.38%XRTX-40.50%
+864%+384%-96%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KALA versus XRTX key metrics
MetricKALAXRTX
Share price$2.71$0.839
Market cap$1.74M$1.88M
1-day change-10.28%-5.73%
Forward P/E—1.05
EPS (TTM)$-321.30$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-26.98M—
52-week high$2,865.00$3.60
52-week low$2.65$0.81
Distance from 52-week high-99.91%-76.69%
Average volume52.52K776.48K
Shares outstanding644.66K2.25M
Employees6—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About KALA BIO

KALA stock →

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About XORTX Therapeutics

XRTX stock →

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.

Health Care · Biotechnology: Pharmaceutical Preparations

KALA vs XRTX FAQ

Which is bigger, KALA BIO or XORTX Therapeutics?

XORTX Therapeutics (XRTX) is larger, with a market capitalization of $1.88M compared with $1.74M for KALA BIO (KALA).

Are KALA BIO and XORTX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons